Enbrel plant approved
This article was originally published in Pharmaceutical Approvals Monthly
Full promotion for Amgen/Wyeth's rheumatoid arthritis agent Enbrel will resume with Dec. 23 approval of Rhode Island manufacturing facility. Amgen estimates that approval of plant will double the overall annual supply of the agent; demand has exceeded supply since 200
You may also be interested in...
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.